DUSP4 ELISA Kit

Name: DUSP4 ELISA Kit
SKU: DEIA-XYA560
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

cell lines

Species Reactivity

Human; Mouse; Rat

Detection Method

sELISA

Intended Use

The DUSP4 Cell-Based ELISA Kit is a convenient, lysate-free, high throughput and sensitive assay kit that can monitor DUSP4 protein expression profile in cells. The kit can be used for measuring the relative amounts of DUSP4 in cultured cells as well as screening for the effects that various treatments, inhibitors (ie. siRNA or chemicals), or activators have on DUSP4.

Contents of Kit

1. 96-Well Cell Culture Clear-Bottom Microplate, 1 Plate
2. 10× TBS, 30 ml (10×). Stability after first use: 1 month at 4°C
3. Quenching Buffer, 24 ml (1×). Stability after first use: 1 month at 4°C
4. Blocking Buffer, 50 ml (1×). Stability after first use: 1 month at 4°C
5. 15× Wash Buffer, 60 ml (15×). Stability after first use: 1 month at 4°C
6. 100× Anti- DUSP4 Antibody, 60 μl (100×). Stability after first use: 1 month at 4°C
7. 100× Anti-GAPDH Antibody, 60 μl (100×). Stability after first use: 1 month at 4°C
8. HRP-Conjugated Anti-Rabbit IgG Antibody, 6 ml (1×). Stability after first use: 1 month at 4°C
9. HRP-Conjugated Anti-Mouse IgG Antibody, 6 ml (1×). Stability after first use: 1 month at 4°C
10. Primary Antibody Diluent, 12 ml (1×). Stability after first use: 1 month at 4°C
11. Ready to Use Substrate, 12 ml (1×). Stability after first use: 1 month at 4°C
12. Stop Solution, 12 ml (1×). Stability after first use: 1 month at 4°C
13. Crystal Violet Solution, 6 ml (1×). Stability after first use: 1 month at 4°C
14. SDS Solution, 24 ml (1×). Stability after first use: 1 month at 4°C
15. Adhesive Plate Seals, 2 Seals. Stability after first use: 1 month at 4°C

Storage

Storage: 4°C
Expiration: 6 months from receipt

Citations

Have you cited DEIA-XYA560 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Genome-wide association study of myocardial infarction, atrial fibrillation, acute stroke, acute kidney injury and delirium after cardiac surgery - a sub-analysis of the RIPHeart-Study

BMC CARDIOVASCULAR DISORDERS

Authors: Westphal, Sabine; Stoppe, Christian; Gruenewald, Matthias; Bein, Berthold; Renner, Jochen; Cremer, Jochen; Coburn, Mark; Schaelte, Gereon; Boening, Andreas; Niemann, Bernd; Kletzin, Frank; Roesner, Jan; Strouhal, Ulrich; Reyher, Christian; Laufenberg-Feldmann, Rita; Ferner, Marion; Brandes, Ivo F.; Bauer, Martin; Kortgen, Andreas; Stehr, Sebastian N.; Wittmann, Maria; Baumgarten, Georg; Struck, Rafael; Meyer-Treschan, Tanja; Kienbaum, Peter; Heringlake, Matthias; Schoen, Julika; Sander, Michael; Treskatsch, Sascha; Smul, Thorsten; Wolwender, Ewa; Schilling, Thomas; Degenhardt, Frauke; Franke, Andre; Mucha, Soeren; Tittmann, Lukas; Kohlhaas, Madeline; Fuernau, Georg; Brosteanu, Oana; Hasenclever, Dirk; Zacharowski, Kai; Meybohm, Patrick; Stevanovic, Ana; Rossaint, Rolf; Felzen, Marc; Goetzenich, Andreas; Moormann, Tobias; Chalk, Katharina; Knuefermann, Pascal; Boehm, Olaf; Hoeft, Andreas; Winterhalter, Michael; Iken, Sonja; Weber, Christian; Wiedenbeck, Carolin; Schwarzmann, Gerhard; Pense, Karin; Zierer, Andreas; Fichtlscherer, Stephan; Goerlach, Gerold; Wollbrueck, Matthias; Boening, Ursula; Weigand, Markus; Strauchmann, Julia; August, Konrad; Morsbach, Kai U.; Paxian, Markus; Reinhard, Konrad; Gruenewald, Matthias; Scholz, Jens; Broch, Ole; Francksen, Helga; Albrecht, Martin; Kuhr, Bernd; Heinze, Hermann; Paarmann, Hauke; Sievers, Hans-Hinrich; Klotz, Stefan; Hachenberg, Thomas; Werner, Christian; Mauff, Susanne; Alms, Angela; Bergt, Stefan; Roewer, Norbert

Abstract

BackgroundThe aim of our study was the identification of genetic variants associated with postoperative complications after cardiac surgery.MethodsWe conducted a prospective, double-blind, multicenter, randomized trial (RIPHeart). We performed a genome-wide association study (GWAS) in 1170 patients of both genders (871 males, 299 females) from the RIPHeart-Study cohort. Patients undergoing non-emergent cardiac surgery were included. Primary endpoint comprises a binary composite complication rate covering atrial fibrillation, delirium, non-fatal myocardial infarction, acute renal failure and/or any new stroke until hospital discharge with a maximum of fourteen days after surgery.ResultsA total of 547,644 genotyped markers were available for analysis. Following quality control and adjustment for clinical covariate, one SNP reached genome-wide significance (PHLPP2, rs78064607, p=3.77x10(-8)) and 139 (adjusted for all other outcomes) SNPs showed promising association with p<1x10(-5) from the GWAS.ConclusionsWe identified several potential loci, in particular PHLPP2, BBS9, RyR2, DUSP4 and HSPA8, associated with new-onset of atrial fibrillation, delirium, myocardial infarction, acute kidney injury and stroke after cardiac surgery.Trial registrationThe study was registered with ClinicalTrials.gov NCT01067703, prospectively registered on 11 Feb 2010.

Expression of DUSP4 transcript variants as a potential biomarker for colorectal cancer

BIOMARKERS IN MEDICINE

Authors: Varela, Tatiana; Laize, Vincent; Conceicao, Natercia; Caldeira, Paulo; Marreiros, Ana; Guerreiro, Horacio; Cancela, M. Leonor

Abstract

Aim: To provide novel data on the expression of DUSP4 transcripts in colorectal cancer (CRC) tissues and to explore their potential as biomarkers. Materials & methods:DUSP4 transcripts expression was determined by quantitative real-time PCR in tissues from 28 CRC patients. Their association with clinicopathological factors and survival analysis was performed. Data from 380 CRC patients available at The Cancer Genome Atlas project were also analyzed. Results: All transcripts were overexpressed in CRC tissues. Variant X1 was the most upregulated and associated with KRAS mutations and poorly differentiated tumor. Overexpression of DUSP4 transcripts could distinguish all tumor stages from normal tissues. Similar results were found in The Cancer Genome Atlas cohort. Conclusion:DUSP4 transcripts have the potential to serve as diagnostic biomarkers for CRC, particularly variant X1.